Cote Elissa S. 4
4 · Vistagen Therapeutics, Inc. · Filed Jun 25, 2025
Insider Transaction Report
Form 4
Cote Elissa S.
Chief Corp Development Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-06-23+150,000→ 150,000 totalExercise: $1.96Exp: 2035-06-23→ Common Stock (150,000 underlying)
Footnotes (2)
- [F1]25% of the stock options vest on June 23, 2026 (the "Vesting Start Date") and 1/36th of the remaining number of shares vest monthly thereafter until all awarded shares are fully vested three (3) years after the Vesting Start Date.
- [F2]The stock options were granted in connection with the Reporting Person's appointment as Chief Corporate Development Officer.